Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928689 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral and Pharmacological Reconsolidation Interference in Misophonia
A Early Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 141
- Enrollment target
NCT05928689 is a Early Phase 1 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 141 participants.
The verdict
NCT05928689, a Early Phase 1 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural mechanisms underlying misophonia's associative learning and memory, the study team will evaluate whether interference with the reconsolidation of a reactivated misophonia memory with propranolol can alleviate aversive reaction to misophonia-related cues.
Interventions
- DRUG Placebo
- BEHAVIORAL Reminder
- DRUG Propranolol Hydrochloride tablet
- BEHAVIORAL Counterconditioning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2024-09-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05928689
The ClinicalTrials.gov registry entry for NCT05928689 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05928689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05928689 about?
NCT05928689 is a clinical study titled "Behavioral and Pharmacological Reconsolidation Interference in Misophonia". One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural...
What is the current status of trial NCT05928689?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 141 participants. The study started on 2023-06-02. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05928689?
The interventions under investigation include: Placebo (DRUG), Reminder (BEHAVIORAL), Propranolol Hydrochloride tablet (DRUG), Counterconditioning (BEHAVIORAL).
Who is sponsoring clinical trial NCT05928689?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.